BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1630816)

  • 1. v-Myc, but not Max, possesses domains that function in both transcription activation and cellular transformation.
    Min S; Taparowsky EJ
    Oncogene; 1992 Aug; 7(8):1531-40. PubMed ID: 1630816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of gene transcription by the amino terminus of the N-Myc protein does not require association with the protein encoded by the retinoblastoma suppressor gene RB1.
    Cziepluch C; Wenzel A; Schürmann J; Schwab M
    Oncogene; 1993 Oct; 8(10):2833-8. PubMed ID: 8378092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transcription activation domains of v-Myc and VP16 interact with common factors required for cellular transformation and proliferation.
    Min S; Crider-Miller SJ; Taparowsky EJ
    Cell Growth Differ; 1994 Jun; 5(6):563-73. PubMed ID: 8086335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis of the carboxy-terminal transforming region of v-Myc: binding to Max is necessary, but not sufficient, for cellular transformation.
    Min S; Mascarenhas NT; Taparowsky EJ
    Oncogene; 1993 Oct; 8(10):2691-701. PubMed ID: 8378081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between Myc and activating transcription factor 2 (ATF2): Myc prolongs the half-life and induces phosphorylation of ATF2.
    Miethe J; Schwartz C; Wottrich K; Wenning D; Klempnauer KH
    Oncogene; 2001 Dec; 20(56):8116-24. PubMed ID: 11781825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
    Fieber W; Schneider ML; Matt T; Kräutler B; Konrat R; Bister K
    J Mol Biol; 2001 Apr; 307(5):1395-410. PubMed ID: 11292350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.
    Echlin DR; Tae HJ; Mitin N; Taparowsky EJ
    Oncogene; 2000 Mar; 19(14):1752-63. PubMed ID: 10777209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The retinoblastoma susceptibility gene product regulates Myc-mediated transcription.
    Adnane J; Robbins PD
    Oncogene; 1995 Jan; 10(2):381-7. PubMed ID: 7838535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
    Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
    Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
    Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
    Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of sequences responsible for the differential regulation of Myc function by delta Max and Max.
    Västrik I; Mäkelä TP; Koskinen PJ; Alitalo K
    Oncogene; 1995 Aug; 11(3):553-60. PubMed ID: 7630640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weak transcriptional activation is sufficient for transformation by v-Myb.
    Engelke U; Whittaker L; Lipsick JS
    Virology; 1995 Apr; 208(2):467-77. PubMed ID: 7747419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. myc, max, and a novel rlf-L-myc fusion protein in small-cell lung cancer.
    Västrik I; Mäkelä TP; Koskinen PJ; Saksela K; Alitalo K
    Princess Takamatsu Symp; 1991; 22():307-18. PubMed ID: 1668890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral mutations enhance the Max binding properties of the vMyc b-HLH-LZ domain.
    Crouch DH; Fisher F; La Rocca SA; Goding CR; Gillespie DA
    Nucleic Acids Res; 2005; 33(16):5235-42. PubMed ID: 16166655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc.
    Austen M; Cerni C; Lüscher-Firzlaff JM; Lüscher B
    Oncogene; 1998 Jul; 17(4):511-20. PubMed ID: 9696045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional activation by human c-myb and v-myb genes.
    Kalkbrenner F; Guehmann S; Moelling K
    Oncogene; 1990 May; 5(5):657-61. PubMed ID: 2189102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-one base pair repeat elements influence the ability of a Gal4-Tax fusion protein to transactivate the HTLV-I long terminal repeat.
    Connor LM; Oxman MN; Brady JN; Marriott SJ
    Virology; 1993 Aug; 195(2):569-77. PubMed ID: 8337832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
    Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
    Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A yeast transcription assay defines distinct rel and dorsal DNA recognition sequences.
    Kamens J; Brent R
    New Biol; 1991 Oct; 3(10):1005-13. PubMed ID: 1768648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the Myc and Max interaction specificity with lambda repressor-HLH domain fusions.
    Marchetti A; Abril-Marti M; Illi B; Cesareni G; Nasi S
    J Mol Biol; 1995 May; 248(3):541-50. PubMed ID: 7752223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.